Bevacizumab and Panitumumab

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using panitumumab together with bevacizumab plus other chemotherapy drugs is generally not recommended. In clinical trials, combining these medications has led to a worse treatment outcome in terms of disease progression and survival rate than using bevacizumab alone plus other chemotherapy drugs. In addition, patients experienced more frequent and serious side effects including rash, dermatitis, diarrhea, dehydration, electrolyte imbalances, mouth ulcers or sores, and pulmonary embolism (blood clots in the lung). It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration of panitumumab in combination with bevacizumab plus chemotherapy appears to reduce survival time and increase adverse reactions and deaths compared to bevacizumab plus chemotherapy alone. The mechanism has not been described. In a randomized, multicenter study on the first-line treatment of 1053 patients with metastatic colorectal carcinoma (mCRC), an interim analysis revealed that the addition of panitumumab to bevacizumab and chemotherapy (oxaliplatin- or irinotecan-based 5-fluorouracil-containing regimen) significantly shortened progression-free survival time relative to bevacizumab and chemotherapy alone (median 8.8 vs 10.5 months). There were also 92 deaths reported in the panitumumab arm, compared to 63 deaths in the non-panitumumab arm. In addition, an increased incidence of National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 3 to 5 adverse reactions was observed in the panitumumab arm (87% vs 72%), including rash/dermatitis acneiform (26% vs 1%), diarrhea (23% vs 12%), dehydration (16% vs 5%, primarily in patients with diarrhea), hypokalemia (10% vs 4%), stomatitis/mucositis (4% vs

Bevacizumab

Generic Name: bevacizumab

Brand name: Avastin, Mvasi

Synonyms: n.a.

What is Bevacizumab?

Panitumumab

Generic Name: panitumumab

Brand name: Vectibix

Synonyms: n.a.

What is Panitumumab?